# Advancements in blood cancer treatments

> Live situation record from CLSTR: https://clstr.news/situations/advancements-in-blood-cancer-treatments
> Updated: 2026-09-24T22:38:26.000Z. Sources: 4. Developments: 2.

Advancements in molecular techniques and targeted therapies are improving the management of various blood cancers, specifically B-cell and T-cell malignancies.

In the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), Bruton’s tyrosine kinase (BTK) inhibitors have become vital. While covalent inhibitors bind irreversibly, new non-covalent or reversible inhibitors, such as pirtobrutinib, are being utilized for patients whose disease has progressed despite previous targeted therapies. 

Additionally, molecular research is providing more precise tools for the clinical intervention of cutaneous T cell lymphoma.

## Timeline

### 2026-09-24: Molecular advancements improve treatment for B-cell and T-cell lymphomas

New molecular techniques and targeted BTK inhibitors are advancing the treatment of B-cell malignancies and cutaneous T cell lymphoma, offering more options for patients with resistant diseases.

2 sources. https://clstr.news/cluster/molecular-advancements-improve-treatment-for-b-cell-and-t-cell-lymphomas

### 2026-09-01: Chronic Lymphocytic Leukemia treatment sees advancements and new drug availability

Advancements in Chronic Lymphocytic Leukemia (CLL) treatment include the availability of pirtobrutinib in Spain for advanced cases, alongside new insights into patient symptom recognition.

2 sources. https://clstr.news/cluster/chronic-lymphocytic-leukemia-treatment-sees-advancements-and-new-drug-availability

---
Cite as: Advancements in blood cancer treatments. CLSTR, https://clstr.news/situations/advancements-in-blood-cancer-treatments